Published in Cancer Weekly, February 15th, 2000
"This patent is one of a number issued or pending in the field of vaccines," according to Dr. David M. Goldenberg, Immunomedics, Inc.
The subject of this new patent involves the "coating" of an alpha-galactose molecule on cancer cells or microorganisms by a fusion protein. Since patients have naturally-occurring antibodies to alpha-galactose, these antibodies can be turned on and can become therapeutic agents against cancers or...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.